Xcout Intel
Episteme Prognostics, Inc.
Episteme Prognostics, Inc. is a healthcare and diagnostics startup headquartered in Brooklyn, New York. The small-team company focuses on prognostic research and medical diagnostic solutions. It aims to develop advanced clinical tools to improve patient outcomes through early disease prediction.
Subscribe to see Episteme Prognostics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Episteme Prognostics, Inc. at a glance
Episteme Prognostics, Inc. is a company headquartered in United States. It has raised at least $19M across the 6 funding rounds on record. Its most recent funding round raised $5.1M in August 2026. Xcout tracks 11 named people at Episteme Prognostics, Inc., including Surajit Dhara (President, Treasurer, and Secretary).
Episteme Prognostics, Inc. leadership
- Surajit DharaPresident, Treasurer, and Secretary
- Surajit DharaChief Executive Officer and Co-Founder
- Steven D. Leach, MDCo-Founder, and Chair of the Scientific Advisory Board
- Arturo Orlacchio, PhDSenior Vice President, Research and Development
- Gregory HoDirector
- Gregory P. HoDirector
5 more named people on record for Episteme Prognostics, Inc., with roles, board committees and tenure — see the full roster →
Episteme Prognostics, Inc. funding rounds
At least $19M raised across the 6 rounds on record. The 5 most recent:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $5.1M | — | |
| SEC Form D filing | $550,000 | — | |
| Seed | $5.5M | — | |
| Series A | $3.7M | — | |
| SEC Form D filing | $4.1M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Recent Episteme Prognostics, Inc. news
- FundingPrivate placement (Form D)
Episteme Prognostics, Inc. competitors
A few of Episteme Prognostics, Inc.'s closest competitors — see the full list of competitors and alternatives →
Prognos Health Inc. is a for-profit healthcare company headquartered in New York, United States, that provides clinical intelligence and health data analytics solutions.
General Prognostics, Inc. (GPx) is a digital biomarker startup operating out of Cambridge and Boston, Massachusetts. The company develops clinically validated digital biomarkers and remote monitoring solutions at the intersection of healthcare and data science.
PrognomIQ Inc. was founded in 2020 and has its primary headquarters located at 1900 Alameda de Las Pulgas in San Mateo, California. The company operates in the biotechnology sector, reimagining early disease detection through multi-omics and advanced data science.
Episteme is a research and development organization founded by Louis Andre and Sam Altman that brings together exceptional cross-disciplinary scientists in-house. The company provides funding, infrastructure, and operational support to help researchers pursue translational science and deploy breakthroughs for real-world impact outside of traditional institutions.
Progentec Diagnostics, Inc. is a healthcare company based in Oklahoma City, Oklahoma, focused on developing biomarker and digital technologies for the proactive care of autoimmune diseases.
Get Episteme Prognostics, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Episteme Prognostics, Inc. in Xcout Intel
- 11 named people with titles, LinkedIn and board committees
- 6 funding rounds with the investors in each, and who they co-invest with
- 1 corporate event with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access